News & Updates
Filter by Specialty:

Durvalumab plus radiotherapy shows promise in unresectable NSCLC
In the treatment of patients with programmed cell death ligand 1 (PD-L1)-positive, unresectable, and locally advanced nonsmall cell lung cancer (NSCLC), the use of durvalumab immunotherapy in combination with curative radiotherapy yields survival gains with tolerable adverse events (AEs), as shown in the results of the phase II DOLPHIN trial.
Durvalumab plus radiotherapy shows promise in unresectable NSCLC
17 Sep 2023
Air pollution exposure may lead to breast cancer
Exposure to high levels of fine particulate matter (PM2.5) appears to contribute to an increased risk of oestrogen receptor (ER)-positive breast cancer, as shown in a study.
Air pollution exposure may lead to breast cancer
17 Sep 2023
ESBL-producing, gentamicin-resistant UTI more common during first week of life
A recent study provides further evidence to support the current recommendations for empirical intravenous treatment with gentamicin and ampicillin for febrile infants younger than 2 months with suspected urinary tract infection (UTI).